No connection

Search Results

MYGN vs PRTC

MYGN
Myriad Genetics, Inc.
BEARISH
Price
$4.91
Market Cap
$459.1M
Sector
Healthcare
AI Confidence
85%
PRTC
PureTech Health plc
NEUTRAL
Price
$18.30
Market Cap
$445.5M
Sector
Healthcare
AI Confidence
75%

Valuation

P/E Ratio
MYGN
--
PRTC
10.7
Forward P/E
MYGN
30.29
PRTC
-36.6
P/B Ratio
MYGN
1.25
PRTC
1.17
P/S Ratio
MYGN
0.82
PRTC
69.7
EV/EBITDA
MYGN
-2.76
PRTC
-36.48

Profitability

Gross Margin
MYGN
68.06%
PRTC
0.0%
Operating Margin
MYGN
-21.41%
PRTC
-2589.52%
Profit Margin
MYGN
-41.29%
PRTC
792.96%
ROE
MYGN
-23.51%
PRTC
9.44%
ROA
MYGN
-7.65%
PRTC
-12.95%

Growth

Revenue Growth
MYGN
-20.8%
PRTC
542.7%
Earnings Growth
MYGN
--
PRTC
--

Financial Health

Debt/Equity
MYGN
0.33
PRTC
0.44
Current Ratio
MYGN
2.67
PRTC
8.49
Quick Ratio
MYGN
1.65
PRTC
8.35

Dividends

Dividend Yield
MYGN
--
PRTC
--
Payout Ratio
MYGN
0.0%
PRTC
0.0%

AI Verdict

MYGN BEARISH

MYGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a fundamental collapse in financial health. While the balance sheet remains liquid with a strong current ratio (2.67) and low debt-to-equity (0.33), these are lagging indicators compared to the alarming -20.80% YoY revenue decline and -41.29% profit margin. The stock is in a long-term secular decline, losing over 82% of its value over five years, and current valuation is supported only by asset value (P/B 1.25) rather than earnings power.

Strengths
Strong liquidity position with a Current Ratio of 2.67
Low leverage with a Debt/Equity ratio of 0.33
Healthy Gross Margin of 68.06% suggesting strong core product value
Risks
Critical operational failure indicated by Piotroski F-Score of 1/9
Significant revenue contraction (-20.80% YoY)
Deeply negative profitability with a -41.29% profit margin
PRTC NEUTRAL

PRTC presents a contradictory financial profile with a stable Piotroski F-Score of 5/9 and a strong liquidity position (Current Ratio 8.49), yet suffers from severe operational inefficiency. While the Graham Number of $24.47 suggests defensive value, the growth-based intrinsic value of $11.90 and a negative forward P/E indicate significant future earnings risk. The massive discrepancy between the reported profit margin (792.96%) and operating margin (-2589.52%) suggests the company is relying on non-operating gains rather than core business profitability. Short-term price momentum is positive, but long-term performance remains deeply depressed.

Strengths
Exceptional short-term liquidity with a Current Ratio of 8.49
Low leverage with a Debt/Equity ratio of 0.44
Explosive year-over-year revenue growth of 542.70%
Risks
Catastrophic operating margins (-2589.52%) indicating high cash burn
Negative forward P/E suggests expected losses in the coming year
Extremely high Price-to-Sales ratio (69.70) indicating overvaluation relative to revenue

Compare Another Pair

MYGN vs PRTC: Head-to-Head Comparison

This page compares Myriad Genetics, Inc. (MYGN) and PureTech Health plc (PRTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile